Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34^th Annual J.P. Morgan Healthcare Conference.

Presentation details are as follows:

Date: Wednesday, January 13, 2016
Time: 11:30 am PT
Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20 ...

The webcast and replay of the presentation will also be accessible under the "Investors/Events" section of the website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[e-mail]
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

[e-mail]
[e-mail]
212-845-4271

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1977152